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Topic reviews need to be robust
To the Editor: I note with interest the review entitled ‘Heart failure in 
sub-Saharan Africa: A clinical approach’.[1]
It is very concerning that the only heart failure guideline published 
in Africa was not referenced in this review.[2] The Heart Failure Society 
of South Africa (HeFSSA) is the only official heart failure society in 
Africa. The HeFSSA guideline was published as a modification of 
the European Society of Cardiology guideline that is quoted in the 
review,[3] specifically to impart a ‘sub-Saharan’ perspective.
If the HeFSSA guideline was included in this review then I’m sure 
the significant omission of the hydralazine-nitrate oral combination 
as a crucial arm of chronic heart failure therapy would not have 
occurred. Considering the demographics of sub-Saharan Africa, 
omitting a therapy that has proven to significantly improve survival, 
reduce hospitalisations and improve quality of life in black Africans,[4] 
is most unfortunate. 
The review also includes perindopril 2 - 4 mg in their list of 
suggested angiotensin-converting enzyme (ACE) inhibitors. The 
HeFSSA guideline excluded this particular drug as no large ran-
domised data exist for the efficacy of this drug in heart failure, not to 
mention the recommended dose. Perindopril 4 mg as a single drug 
had no benefit on reducing stroke,[5] and perindopril 8 mg was need-
ed to reduce events in high-risk cardiovascular patients.[6] The effec-
tive dose in heart failure is unknown. Telmisartan is also included in 
this review. No heart failure end point and effective dose data exist for 
this drug either and it is not listed in the HeFSSA guideline.
The comments in the review on a heart rate target of <75 beats/
minute with beta-blocker therapy are confusing and ill advised for the 
heart failure practitioner. No large, randomised beta-blocker trial that 
showed improved survival and reduced hospitalisations in chronic 
heart failure therapy has used heart rate as a target in therapy. Target 
beta-blocker doses were aimed for in the trials and should be aimed for 
in clinical therapy. The statement in this review confuses the systolic 
heart failure treatment (SHIFT)[7] trial and extrapolates inappropriately 
the heart rate data to beta-blocker therapy with no randomised evi-
dence to support this advice. This advice in the review will also result in 
underdosing of beta-blocker therapy. If this review[1] is to be used as a 
reference for doctors to guide their heart failure therapy, then I strongly 
suggest corrections should be published in a revised review.
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Ntusi et al. respond: We are grateful for the opportunity to respond 
to the comments made by Dr Klug in reference to our article titled 
‘Heart Failure in sub-Saharan Africa: A clinical approach’,[1] which 
formed part of the recent cardiovascular disease (CVD) continuing 
medical education (CME) in the Journal. Indeed, the heart failure 
(HF) guideline[2] published under the auspices of the Heart Failure 
Society of South Africa (HeFSSA) was not cited in this review. 
We admit this was an important omission. However, our review 
liberally cited the European Society of Cardiology (ESC) guideline 
on the management of HF,[3] upon which the HeFSSA guideline is 
also heavily premised.
While we acknowledge the importance of the HeFSSA guideline 
and its place in the management of HF in South Africa (SA), the 
HF review, which was not meant to replace the current treatment 
recommendations of HeFSSA, like all the articles that formed the 
CVD CME, focused on simple, pragmatic clinical approaches to 
common cardiovascular challenges encountered at the primary 
level of healthcare, with the aim of not being overly complex. As 
such, in this successful collaboration, the CME articles were jointly 
produced by SA cardiologists and family physicians with the dual 
objectives of empowering doctors who manage these conditions in 
primary care settings in SA and improving the care of CVD patients 
in such settings. In the first issue, HF,[1] dyspnoea,[4] hypertension 
in the young[5] and valvular heart disease[6] were reviewed. In the 
second issue, infective endocarditis[7] and pericardial disease[8] 
were discussed. The final edition provided an evidence-based and 
pragmatic approach to chest pain and acute coronary syndromes[9] 
and suspected tachyarrhythmias in the emergency room.[10] 
Upon this background, the main goals of the HF review were to: 
(i) emphasise how to make the diagnosis of HF; (ii) highlight clues 
for recognition of the underlying aetiology of HF; (iii) review the 
pathophysiology of HF; and (iv) provide a simplified approach to 
management of HF.
The lack of recommendations relating to use of hydralazine-
nitrate oral combination in our HF review, in particular for 
black African patients, are indeed a notable omission. In the 
SA public sector, particularly at the primary healthcare level, 
the availability of hydralazine is haphazard. Further, while this 
combination therapy is associated with improved survival, 
reduced hospitalisation and improved quality of life in black 
African patients, compared with placebo, it is comparable with 
the mortality benefit of angiotensin converting enzyme (ACE) 
inhibitors, which are much more freely available and accessible 
in primary health centres around SA. Moreover, this combination 
therapy should be used with caution in certain patients.[11] In 
addition, the recently performed Bi treatment with hydralazine/
nitrates v. placebo in black Africans admitted with acute HF 
(BA-HEF) study had to be terminated prematurely due to poor 
recruitment and was neutral.[12] One of the main reasons for poor 
recruitment was hypotension.
Even though perindopril does not have randomised trial data 
supporting its specific use in HF, in certain provinces within SA 
such as the Eastern Cape, it has been the only ACE inhibitor 
available within the state sector, and it is still included (at the doses 
stated in our HF review) in the ESC guidelines.[3] We have opted to 
adopt a pragmatic approach that is relevant to primary healthcare 
practitioners in SA. 
The comments relating to target heart rate with beta-blockers 
are noted and we share the same views as Dr Klug. Indeed, there 
is no evidence of improved outcomes with beta-blockers titrated 
to a specific target heart rate. However, there is strong evidence 
that heart rate reduction in HF is associated with improved 
survival,[13,14] although the optimal heart rate target has not been 
established. 
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It is our hope that our review will provide a simple and pragmatic 
clinical approach to the management of HF at the primary healthcare 
level in SA in order to improve the lives of SA HF patients.
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